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Introduction
An increased intake of the long-chain omega-3 fatty acids (LC n-3 PUFAs) eicosapentaenoic acid (EPA, C20:5) and docosahexaenoic acid (DHA, C22:6) has been associated with a reduced risk for several chronic inflammatory diseases such as rheumatoid arthritis [15] , neuropsychiatric diseases [25, 13] , atherosclerosis and cardiovascular diseases [7, 17] . However, the underlying molecular acid (AA, C20:4 n-6) by cyclooxygenase and 5-lipoxygenase action (i.e. prostaglandins and leukotrienes), only limited information is available about the formation and biological role of hydroxy, epoxy and dihydroxy FA derived from LC n-3 PUFAs. Recent studies have shown that particularly epoxy FA from LC n-3 PUFAs possess highly potent anti-arrhythmic [36] , vasodilatory [1] and anti-thrombotic effects [11] . Hydroxylated FAs serve as precursors for pro-resolving signaling molecules, i.e. resolvins and (neuro)protectins which actively mediate the resolution of inflammation [38, 31, 30] .
Profiling of oxylipin patterns in response to LC n-3 PUFA supplementation in humans may assist to deduce their mechanisms of action. Moreover, it may provide novel biomarkers facilitating the investigation of the effects of LC n-3 PUFAs. Several human studies documented changes of hydroxy, epoxy and dihydroxy FA levels in serum and plasma following treatment with LC n-3 PUFA regarding free oxylipins [14, 28] or total oxylipins (sum of both free and esterified) after conjugate cleavage by saponification [34, 12, 29, 8] . Applied LC n-3 PUFA doses and treatment duration varied considerably among the long term studies: 11.0 ± 2.0 mg/kg/d (∼0.8 g/d) as ethyl esters for 4 weeks [12] ; 0.84-1.74 g/d as ethyl esters for 4-8 weeks [8] ; 3.0 g/d as re-esterified triglycerides for twelve weeks [28] ; 4.0 g/d LC n-3 PUFAs as ethyl esters for 4 weeks [34] and 6.0 g/d EPA/DHA as ethyl esters for 3 weeks [14] . In addition to the varying study designs, the strong inter-individual differences in the blood oxylipin levels, as discussed in [27] , make it complicated to compare different studies. When comparing the reported baseline levels of free serum and plasma levels against total plasma oxylipins, it becomes apparent that the major portion of hydroxy, epoxy and dihydroxy FA are found mainly esterified in the plasma [27] . Interestingly, with and without saponification most dihydroxy FA were detected in the same range indicating that no or a very low portion of these lipid mediators in plasma is found in lipids or triglycerides. LC n-3 PUFA intake causes both a change in the pattern of total oxylipins [34, 12] as well as in the levels of free oxylipins [14, 28, 29] . However, there is no information on how the changes in esterified and free oxylipins are correlated. Therefore, the aim of this study was to determine the impact of a supplementation of LC n-3 PUFAs on the patterns of hydroxy, epoxy and dihydroxy FA species and their ratio between free and total levels in plasma. Using a targeted metabolomics approach, we simultaneously quantified 50 oxylipins in human plasma before and after twelve weeks of supplementation with EPA and DHA ethyl esters.
Materials and methods
This investigator initiated study was designed and conducted according to the principles of the Good Clinical Practice Guidelines laid down in the Declaration of Helsinki and was approved by an independent Research Ethics Board (Freiburg Ethics Commission International).
Subjects
Ten subjects were recruited via newspaper advertisements and screened in the Institute of Food Science and Human Nutrition at the Leibniz University Hannover, Germany. The exclusion criteria were age 30 and >75 years, body mass index >35 kg/m 2 , type 1 and 2 diabetes, cancer, coronary heart disease, renal failure, liver disease, bleeding disorders, gastrointestinal disorders (e.g. Colitis ulcerosa, Crohn's disease, chronic pancreatitis, pancreatic insufficiency, coeliac disease, enterocolitis, cholestasis, short bowel syndrome), surgical operation in the gastrointestinal system (e.g. gastrectomy, stomach reduction, stomach tape or balloon), hormonal disorders (e.g. hyperthyroidism and Cushing's disease), high intake of oily fish (>2 times per week), intake of lipid-lowering drugs (statins, fibrates, ezetimibe, and niacin) or nutritional supplements (including LC n-3 PUFAs, phytosterols and polyglucosamin), intake of anticoagulant drugs. Only participants that fulfilled the criteria were included in the study population. All subjects gave their written informed consent to take part in the study.
Study design
Subjects were supplemented with LC n-3 PUFA capsules for a period of twelve weeks. Soft gelatin capsules contained reesterified fish oil (840 mg/capsule, Dr. Loges GmbH, Winsen, Germany). The oil contained 330 mg/g EPA and 220 mg/g DHA ethyl ester. The total amount of LC n-3 PUFA ethyl esters (C20:5, C22:6, C18:3, C18:4, C20:4, C21:5, C22:5) was 640 mg/g Moreover the oil contained 2.8 mg/g tocopheroles as antioxidant. Subjects were instructed to ingest four capsules per day (two in the morning and two in the evening together with food and a glass of water). The daily intake was 1.1 g EPA ethyl ester and 0.74 g DHA ethyl ester. Subjects were requested to abstain from eating fatty fish during the intervention period, while other exercise and dietary habits should be maintained. During the two visits, baseline (t 0 ) and after twelve weeks of intervention (t 12 ) fasting blood was collected. Additionally, at t 0 height and weight of the subjects were measured. The subjects' compliance was assessed by a questionnaire, capsuleintake diaries and a count of left-over capsules at the end of the intervention period.
Sample collection and analysis
Blood samples were collected by venipuncture of an arm vein into EDTA-monovettes (Sarstedt, Germany) in the morning between 6:00 and 9:30 a.m. after overnight fasting. Plasma was prepared directly by centrifugation (2000 × g, 10 min, 10 • C), transferred into 15 mL falcon tubes (Becton Dickinson) and immediately frozen and stored at −80 • C awaiting LC-MS analysis. Other sets of EDTA-whole blood samples collected simultaneously were sent to an external laboratory (Omegametrix, Martinsried, Germany), where the FA composition in erythrocyte membranes was determined as previously described [10, 20] . Results are presented as a percentage of the total identified FAs.
Oxylipins were analyzed in plasma samples as free oxylipins and after saponification to determine the sum of both free and esterified oxylipins as previously described [3] . In brief, 250 L of plasma were mixed with an equal volume of methanol. After addition of 300 L aqueous sodium hydroxide (10 M) the samples were incubated at 60 • C for 30 min. Following neutralization with 50% acetic acid the oxylipins were extracted by solid phase extraction and quantified by liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS) as previously described [27] . Only oxylipins which exceeded the limit of quantification in ≥95% of each sample set were used for data analysis.
Data analysis and statistics
PUFA composition in erythrocyte membranes ( Fig. 1) as well as concentrations of free and total oxylipins in plasma (Table 1) is presented as mean ± standard error (SE). The sample sets were analyzed for their distribution by the Kolmogorov-Smirnov test. Differences between time points within groups were analyzed by t-test for paired samples. Changes in the concentration (c) were calculated individually for each subject at each time point (0 and 12) as %, calculated by: % = 100 × (c t12 − c t0 )/c t0 . Results are shown as mean change ± SE (Table 1 and Fig. S1 ). To compare their relative distribution, the oxylipins were grouped by substrate (Fig. S2) . For the calculation, the sum of the median values of the analyzed Table 1 Concentration of total (sum of esterified and free) and free oxylipins in plasma of healthy human subjects (n = 10) at baseline (t0) and after twelve weeks (t12) of treatment with LC n-3 PUFA. Mean relative change from t0 after twelve weeks of treatment with LC n-3 PUFA was calculated individually for each subject. All results are shown as the mean ± SE. Significant differences between the two time points were determined by dependent sample t-test.
Total oxylipins
Free oxylipins
Relative change from t0 [%]
Relative change from t0 [%] oxylipins from each LC PUFA (18:2 n-6, 18:3 n-3, 20:4 n-6, 20:5 n-3 and 22:6 n-3) was divided by the sum of the medians for all oxylipins. All statistical analyses were carried out with SPSS software (Version 21, SPSS Inc., Chicago, IL, USA). Statistical significance was generally accepted at p < 0.05.
Results
Included subjects (5 male; 5 female) had an average age of 63 years (range: 46-70 years) and were slightly overweight with a body mass index of 26 kg/m 2 (range: 21-35 kg/m 2 ). No changes in body weight and body mass index as well as dietary and lifestyle habits were documented after the intervention period. The LC n-3 PUFA capsules were well tolerated. Compliance was high (>90%) and all subjects completed the study. No obvious sex specific differences in the oxylipin level and in the response to LC n-3 PUFA supplementation were observed (Table S1) , thus all analyses were carried out for the whole study collective.
The percentage of total FAs for linoleic acid (LA C18:2 n-6), AA, alpha-linolenic acid (ALA C18:3 n-3), EPA and DHA in erythrocyte membranes (Fig. 1) as well as concentration of total and free hydroxy FA, epoxy FA and dihydroxy FA in plasma (Table 1) were quantified in blood samples of all ten study participants before and 2 . Ratio between total (sum of esterified and free) and free oxylipins (total:free ratio) in plasma at baseline (t0) and after twelve weeks (t12) of treatment with LC n-3 PUFA. Ratios of hydroxy, epoxy and dihydroxy fatty acids derived from (A) linoleic acid (LA C18:2 n-6), (B) arachidonic acid (AA C20:4 n-6), (C) alpha-linolenic acid (ALA C18:3 n-3), (D) eicosapentaenoic acid (EPA C20:5 n-3) and (E) docosahexaenoic acid (DHA C22:6 n-3) are shown. Significant differences were determined by dependent sample t-test. * p < 0.05, ** p < 0.005. after twelve weeks of treatment with LC n-3 PUFA. All variables were normally distributed.
Relative fatty acid composition of erythrocyte membranes
After twelve weeks of LC n-3 PUFA treatment the relative EPA and DHA content was significantly increased (Fig. 1) . Correspondingly, the relative LA, AA and ALA levels were slightly decreased, although not significantly. At time point t 12 , a significant change of EPA (200 ± 39% of baseline) and DHA (23 ± 5.7% of baseline) content was calculated on the individual subject level.
Total and free oxylipin levels at baseline
Among the 50 analyzed oxylipins, 46 could be detected in the samples after saponification representing the total oxylipins in plasma and 40 were quantified as free oxylipins. Interindividual variation for both total and free oxylipins in plasma was high (mean SE 14 ± 7%). Concentrations of total plasma oxylipins are, for most analytes, considerably higher compared to free plasma oxylipins (Table 1) leading to a high total:freeratio (Fig. 2) . Particularly, the concentrations of total LA-and AA-derived hydroxy and epoxy FAs were 50-to 350-times higher than those of the free oxylipins. The total:free plasma oxylipin ratio for other hydroxy FA ranged between 10 and 50. In contrast, levels of several dihydroxy FAs (12,13-DiHOME, 11,12-DiHETrE, 14,15-DiHETrE, 15,16-DiHODE, 17,18-DiHETE, 10,11-DiHDPE, 13,14-DiHDPE, 16,17-DiHDPE, 19,20-DiHDPE) were in a similar range with and without conjugate cleavage (Table 1) resulting in total:free-ratios of 1-3 (Fig. 2) . This is consistent with earlier findings that dihydroxy FA are only or dominantly present non-esterified in plasma [27] .
Comparing the relative distribution of total analyzed oxylipin concentrations grouped by substrate, the AA-derived oxylipins are the most prominent fraction followed by LA-derived metabolites (56% and 37% at t 0 , respectively). The LC n-3 PUFA metabolites together summed up to less than 10% of total of quantified analytes (Fig. 3A) . Looking at the same set of analytes, this distribution is completely different among the free oxylipins (Fig. 3B) . The percentage of oxylipins from the five different LC PUFAs was more evenly distributed, with the LA-and ALA-derived metabolites being most abundant. The LC n-3 PUFA-derived oxylipins together summed up to 43% of total at t 0 .
In the fraction of total plasma oxylipins, hydroxy FAs were generally present in highest concentrations followed by epoxy and dihydroxy FAs (Table 1) . When comparing the concentrations of the lipid mediators derived from each PUFA individually, large differences in the concentrations of the most abundant oxylipins and the lowest ones were found, spanning, e.g. over a range of more than 3 orders of magnitude for AA (15-HETE vs. 14,15-DiHETrE). The plasma levels of free oxylipins were in a more narrow concentration range, e.g. for AA-derived oxylipins between 0.2 and 1.1 nM. As a consequence the pattern of the relative concentration of the free and total plasma oxylipins of each PUFA showed pronounced differences (Fig. S2) . For AA the relative pattern of the analyzed oxylipins was similar, except for the relative low concentration of DiHETrEs in fractions after conjugate cleavage. The most abundant hydroxy FA in total and free plasma was 15-HETE, while all three analyzed epoxides of AA were found in the same concentration range (Table 1 and Fig. S1 ). The relative low concentration of dihydroxy FAs in the total oxylipin fraction changed the observed pattern between free and total plasma oxylipins of ALA and EPA (Fig. 2) 
Changes in total and free oxylipin levels following LC n-3 PUFA supplementation
Because of the high interindividual differences in the oxylipin levels, the changes in oxylipin patterns were additionally calculated as mean percent change based on individual changes in plasma oxylipin concentrations (Table 1 and Fig. S1 ). The average absolute concentrations before and after intervention are also shown in Table 1 and gender specific in Table S1 . The total plasma concentrations of EPA-derived oxylipins were highly increased with a mean increase of 70-150% (Table 1 and Fig. S1 ). Simultaneously, decreased levels of AA-derived oxylipins were observed with a mean change of about −30% (Table 1 and Fig. S1 ). Changes in EPA-and AA-metabolites were significant with a few exceptions (12-HEPE, 15-HEPE, 11(12)-EpETrE). The massive change in the total plasma oxylipins derived from LC n-3 PUFA supplementation becomes even more apparent regarding the relative distribution of all analyzed oxylipins (Fig. 3A) . The EPA oxylipins increased from 3 to 9% and AA-derived oxylipins decreased from 56 to 40% of the sum of total plasma oxylipins (Fig. 3A) . The concentration of total plasma LA-and ALA-derived oxylipins decreased in response to treatment and was significant for 9(10)-EpOME, 12(13)-EpOME, 15(16)-EPODE, 15,16-DiHODE 9,10-DiHODE (Table 1) . No effect of LC n-3 PUFA supplementation was observed on total plasma epoxy and dihydroxy FA from DHA.
Similar effects of n-3 PUFA treatment were observed on free plasma oxylipin levels, though the absolute changes in concentrations were lower and fewer reached significance (Table 1 and Fig.  S1 ). The EPA-derived oxylipins were highly increased, up to 150%, while AA-derived oxylipins were decreased by 10-40% (Table 1) . A slight decrease in ALA-metabolites -although not significant -was observed, while no effect was seen for LA-and DHA-metabolites (Table 1, Fig. S1 ).
Changes in the total:free plasma oxylipin ratio following LC n-3 PUFA supplementation
The similar change in total and free plasma oxylipins is also reflected by a constant total:free plasma oxylipin ratio after LC n-3 PUFA treatment (Fig. 2) . A slight -but significantlower total:free ratio in plasma following LC n-3 PUFA supplementation was observed for 12,13-DiHOME, 5-HETE, 15-HETE, 14,15-DiHETrE, 15,16-DiHODE, 17,18-DiHETE and 19,20-DiHDPE). For EPA-derived hydroxy FAs about 1.7 fold higher ratios were observed post n-3 PUFA treatment. Thus, the ratios of free and esterified hydroxy, epoxy and dihydroxy FAs are overall not affected by the change in the oxylipin patterns caused by LC n-3 PUFA intake.
Discussion
In this study, we present quantitative data on 40 free and 46 total oxylipin levels in plasma from a cohort of ten subjects before and after supplementation with LC n-3 PUFAs for a period of twelve weeks. The increase of relative EPA and DHA concentration in erythrocyte membranes in the treatment group demonstrated that subjects responded to the LC n-3 PUFA supplementation. The pattern of hydroxy, epoxy and dihydroxy FAs in both free and total plasma oxylipins are significantly modulated by LC n-3 PUFA treatment. The strongest changes were observed in EPA-oxylipins, where particularly CYP-derived epoxides were consistently elevated. This is consistent with all previous studies investigating the effects of dietary LC n-3 PUFA supplementation on the human plasma oxylipin pattern [34, 12, 14, 28, 29, 8] . Because of this massive increase and the biological activity of EPA epoxides on the cardiovascular system [36, 1, 11] , it is reasonable to expect that these mediators might be at least in part responsible for the cardio-protective effects described for LC n-3 PUFA [7, 17, 3] . Though the subjects received an equal daily dose of DHA, which is also confirmed by the significantly elevated relative DHA content in erythrocyte membranes, no changes in EpDPEs and its sEH hydrolyses products were observed. This is also well in line with previous studies describing unchanged or slightly elevated levels of CYP derived EpDPEs and DiHDPEs [28, 29, 14, 12] . Fischer and Konkel et al., however, observed a significant increase in DHA epoxides and diols, which was also less pronounced than that of EPA-derived metabolites [8] . With respect to HEPEs, we found with an increase of 100-250% of all measured total HEPEs similar results as Fischer and Konkel, while the increase was less pronounced for free HEPEs (Table 1) . It should be noted that hydroxy-DHAs were not monitored in this study and thus a potential increase in these metabolites could not be detected. However, the massive increase in EPA metabolites makes it reasonable to speculate that -in case hydroxy, epoxy, or dihydroxy FAs are a driving force for the effects of LC n-3 PUFA action on human health -EPA-derived oxylipins play a major role.
Our results could also substantiate another common explanation for the effects of LC n-3 PUFA, which is the displacement of AA and thereby inhibiting the formation of its lipid mediators. Though the treatment did not lead to a change in the relative AA content in erythrocytes, the mean plasma concentration of AA-oxylipins, as well as the individual plasma concentration of the subjects were decreased ( Fig. 1 and Table 1 ). The change of AA-metabolites in the total plasma oxylipin fraction was much more pronounced indicating particularly a displacement of esterified AA-derived oxylipins after twelve weeks of LC n-3 PUFA supplementation (Fig. 1) . This reduction in AA-derived oxylipin concentrations may be explained by a competition of the LC n-3 PUFA for the same enzymes as it has already been described for COX and LOX [37] or CYP pathways [8] . However, since the FA pattern in plasma was not determined it could also be possible that the shift in plasma oxylipins is caused by a shift in the plasma FA levels.
Taken together the increase of EPA-derived oxylipins and the decrease in AA-derived oxylipins after twelve weeks of LC n-3 PUFA treatment led to a pronounced shift in the overall pattern of oxylipins (Table 1, Figs. 3 S1 and S3) . However, the key question is in which tissue and which cellular compartment the changes have to arise to cause biological effects. Generally, it is believed that oxylipins act largely in an autocrine or paracrine fashion and thus locally in the tissue were they are formed [33] . With exception of direct effects on the endothelia in the vascular system, the quantification of oxylipins in plasma or serum can therefore largely be regarded as a proxy reflecting the situation in the tissue of interest (which is not or difficult to obtain for analysis). Having said that, one must ask: Are none-esterified (free) oxylipins, total plasma oxylipins or even another specific fraction, such as oxylipins in lipoproteins [32, 18] , or specific classes of lipids best suited to investigate the biology of oxylipins? The answer will be different dependent on the physiological or pathophysiological parameter investigated as well as for the class of lipid mediator regarded. However, with respect to the investigation of the impact of LC n-3 PUFA treatment on the levels of hydroxy, epoxy, and dihydroxy FAs in plasma, our study shows that both free and total plasma oxylipins support overall similar conclusions. The modulation of the oxylipin profile caused by twelve weeks of LC n-3 PUFA supplementation -i.e. an increase of EPA-derived oxylipins and a decrease in AA-derived oxylipins -is reflected by both parameters with an overall constant ratio between free and total plasma oxylipins. Thus, both parameters are comparable biomarkers to assess the effect of nutrition on this class of lipid mediators.
Nevertheless, for each study aiming to investigate biological effects of LC n-3 PUFA it should be carefully decided whether it is more appropriate to focus on free or total (after saponification) oxylipins in plasma. The total hydroxy, epoxy, and dihydroxy FAs are present in concentrations which can be well detected and changes in EPA and AA levels are more pronounced. Though this fraction appears to be a more suitable biomarker for LC n-3 PUFA treatment, it should be kept in mind that the biological role of esterified oxylipins is not clear and that they may reflect a pool of lipid mediators which have to be released to elicit biological effects [40] . Unbound, i.e. "free" oxylipins, reflect the biological active form, though the molecular target of most hydroxy, epoxy, and dihydroxy FAs is not clear up to now. The free plasma concentration, particularly of LC n-3 PUFA derived oxylipins, is so low that analysis is challenging, making it difficult to assess the effect of LC n-3 PUFA treatment on several hydroxy, epoxy, and dihydroxy FAs (Table 1) . Ultimately, only a correlation of the oxylipin concentration in the tissue of interest with the targeted biological/physiological effect will answer the question whether the free or the bound/total fraction of oxylipins in plasma is the most suitable analytical parameter assessing modulation of lipid mediators by LC n-3 PUFA.
Limitations of the study
The effects were only analyzed in 10 human subjects making it possible that the high variation of the oxylipin levels might mask biologically significant differences in the oxylipin pattern or its ratios. The regarded hydroxy, epoxy and dihydroxy FAs do not reflect all possibly formed oxylipins, because of limited coverage of the analytical method used. Particularly, the levels of hydroxy DHA-metabolites, resolvins, protectins and maresins as found in human plasma [6] were not regarded in the present study. Because of the saponification used to assess total oxylipins several lipid mediators, e.g. prostanoids, are degraded making it impossible to compare the levels of these oxylipins [9] . Analytical methods utilizing improved techniques to liberate esterified oxylipins, e.g. by enzymatic treatment together with a comprehensive detection would allow a more complete picture on oxylipin levels and their biology in clinical and experimental studies.
Conclusion
Twelve weeks of LC n-3 PUFA supplementation induced changes in both free and total oxylipin patterns. Especially hydroxy, epoxy, and dihydroxy EPA were increased, while the corresponding AA derivatives were decreased. The modulation of total plasma oxylipins was more pronounced compared to free oxylipins. Thus, the majority of hydroxy, epoxy and dihydroxy EPA formed during twelve weeks of supplementation are found in the pool of esterified oxylipins in blood lipids. Despite these changes, the free:total ratio remained overall unchanged indicating an equilibrium between the free and esterified oxylipins of LC PUFA. Accordingly, both direct analysis and analysis after saponification are suitable analytical techniques assessing the individual status of hydroxy, epoxy and dihydroxy LC PUFA leading overall to similar results.
